Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

CBAY - CymaBay Therapeutics, Inc.

IEX Last Trade
32.48
32.480   100.000%

Share volume: 0
Last Updated: Thu 21 Mar 2024 08:08:43 PM CET
Pharmaceutical Preparation Manufacturing : 2.72%

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
37%
Profitability 43%
Dept financing 3%
Liquidity 45%
Performance 37%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
40.67%
2 Year
492.70%
Key data
Stock price
$32.48
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$23.11 - $32.50
52 WEEK CHANGE
$32.73
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
114.724 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Sujal Shah
Region: US
Website: cymabay.com
Employees: 60
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing

CymaBay Therapeutics, Inc. focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics.

Recent news